CTNM insider trading
HealthcareContineum Therapeutics, Inc.: insider trade history from SEC Form 4 filings.
About Contineum Therapeutics, Inc.
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain. It also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor which is in Phase 2 clinical trial to treat depression and relapse remitting MS; and CTX-343, a peripherally restricted LPA1R antagonist which is a brain penetrant drug candidate. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
Company website: www.contineum-tx.com
CTNM insider activity at a glance
FilingIQ tracks 58 insider transactions for CTNM in filings since Apr 11, 2024. The most recent transaction is dated Sep 8, 2026.
Across the full history, 0 open-market purchases
and 34 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
Latest CTNM Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for CTNM?
- FilingIQ tracks 58 Form 4 insider transactions for CTNM (Contineum Therapeutics, Inc.), covering filings from Apr 11, 2024 onwards. 6 of those are dated within the last 90 days.
- Are CTNM insiders net buyers or net sellers?
- Across the full Form 4 history for CTNM, 0 transactions (0%) were open-market purchases and 34 (59%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does CTNM insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is CTNM in?
- Contineum Therapeutics, Inc. (CTNM) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $522.37M.
Methodology & sources
Every CTNM insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.